Business
ProQR Announces Third Quarter 2025 Operating and Financial Results
Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseasesInitiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerability, and PK data from Cohort 1 expected by year-end, and target engagement data from all cohorts in H1 2026€ 106.9 million cash and cash equivalents as of end Q3 – providing runway into mid-2027 LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:
About this update from Proqr Therapeutics N.v.
[{"type":"image","alt":"ProQR Therapeutics N.V.","displaySize":"","headline":null,"caption":"ProQR Therapeutics N.V.","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/044666b5bdc9e0d99686bfed8e7211d3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4HUbXKqR88bsVsQR5pPVmw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/044666b5bdc9e0d99686bfed8e7211d3","width":150,"height":150}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseases","length":109,"tagName":"p"}]},{"val":[{"type":"text","content":"Initiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerability, and PK data from Cohort 1 expected by year-end, and target engagement data from all cohorts in H1 2026","length":196,"tagName":"p"}]},{"val":[{"type":"text","content":"€ 106.9 million cash and cash equivalents as of end Q3 – providing runway into mid-2027","length":87,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":392,"olType":false},{"type":"text","content":"LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the third quarter ended September 30, 2025, and provided a business update.","length":404,"tagName":"p"},{"type":"text","content":"“Last month we achieved an important milestone with the CTA authorization and are initiating our first-in-human study for AX-0810, marking a significant step forward for both this program and our Axiomer RNA editing platform,” said Daniel A. de Boer, Founder and Chief Executive Officer of ProQR. “This study represents the first clinical evaluation of an Axiomer editing oligonucleotide and positions us to deliver initial safety and PK data before year-end, followed by target engagement data in the first half of 2026. Supported by our strong cash position providing runway into mid-2027, we continue to advance our broader pipeline, platform, and partnership activities, executing on our st...